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Background 
Mul$ple	  myeloma	  (MM)	  is	  the	  second	  most	  common	  hematopoie$c	  
neoplasm,	  accoun$ng	  for	  22,000	  new	  cases	  in	  the	  U.S.	  each	  year	  and	  2%	  of	  
all	  cancer	  deaths.	  MM	  is	  characterized	  by	  the	  prolifera$on	  of	  malignant	  
plasma	  cells	  in	  the	  bone	  marrow,	  and	  is	  a	  mostly	  incurable	  disease	  due	  to	  the	  
gene$c	  heterogeneity	  between	  MM	  pa$ents,	  as	  well	  as	  within	  a	  single	  
pa$ent	  due	  to	  the	  presence	  of	  subclonal	  tumor	  popula$ons.	  Addressing	  this	  
heterogeneity	  requires	  an	  individualized	  treatment	  approach	  with	  a	  wide	  
array	  of	  drugs	  that	  have	  diﬀerent	  targets.	  Previously	  in	  the	  Van	  Ness	  
laboratory,	  it	  was	  demonstrated	  that	  the	  polycomb	  group	  protein	  enhancer	  
of	  zeste	  homolog	  2	  (EZH2)	  acts	  as	  an	  oncogene	  in	  mul$ple	  myeloma1.	  EZH2	  is	  
the	  cataly$c	  subunit	  of	  the	  polycomb	  repressive	  complex	  2	  (PRC2),	  
repressing	  gene	  expression	  via	  the	  methyla$on	  of	  histone	  H3	  on	  lysine	  27	  
(H3K27)2.	  The	  epigene$c	  inac$va$on	  of	  tumor	  suppressor	  genes,	  presumably	  
via	  EZH2,	  has	  been	  associated	  with	  a	  poor	  prognosis	  in	  mul$ple	  myeloma3.	  
Addi$onally,	  there	  is	  an	  enrichment	  of	  H3K27me3	  at	  genes	  that	  are	  
commonly	  underexpressed	  in	  mul$ple	  myeloma	  cells,	  including	  known	  EZH2	  
targets,	  which	  could	  likely	  be	  due	  to	  increased	  EZH2	  ac$vity4.	  Overexpression	  
of	  EZH2,	  as	  well	  as	  EZH2	  muta$ons,	  have	  been	  found	  in	  other	  cancers,	  such	  
as	  prostate	  and	  breast	  cancer	  and	  lymphoma2,5,	  leading	  to	  the	  development	  
of	  several	  novel	  EZH2	  inhibitors.	  Two	  of	  these	  inhibitors	  are	  GSK126	  
(GlaxoSmith	  Kline)	  and	  EPZ-­‐6438	  (Epizyme),	  which	  are	  both	  highly	  selec$ve,	  
compe$$ve	  small-­‐molecule	  inhibitors	  of	  EZH2	  methyltransferase	  ac$vity.	  In	  
recent	  studies,	  GSK126	  and	  EPZ-­‐6438	  both	  inhibited	  the	  prolifera$on	  of	  EZH2	  
mutant	  diﬀuse	  large	  B-­‐cell	  lymphoma	  (DLBCL)	  cells	  and	  inhibited	  the	  growth	  
of	  EZH2	  mutant	  DLBCL	  xenogra`s	  in	  mice2,6.	  Because	  of	  these	  recent	  
developments,	  we	  hypothesize	  that	  EZH2	  inhibi$on	  will	  reduce	  viability	  of	  
human	  MM	  cell	  lines	  (HMCLs)	  in	  vitro,	  and	  that	  the	  diﬀerences	  seen	  in	  EZH2	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Results 
GSK126	  and	  EPZ-­‐6438	  were	  used	  in	  single-­‐agent	  dose	  response	  viability	  assays	  with	  human	  
mul$ple	  myeloma	  cell	  lines	  (HMCLs)	  containing	  the	  lowest	  and	  highest	  levels	  of	  EZH2	  expression.	  
By	  determining	  the	  IC50s	  of	  GSK126	  and	  EPZ-­‐6438	  in	  these	  cell	  lines,	  it	  could	  be	  determined	  if	  
there	  were	  diﬀerences	  in	  sensi$vity	  to	  EZH2	  inhibi$on	  that	  were	  dependent	  on	  EZH2	  expression.	  
Addi$onally,	  it	  was	  determined	  whether	  or	  not	  EZH2	  inhibi$on	  occurred	  in	  these	  cell	  lines	  by	  
extrac$ng	  histones	  in	  HMCLs	  a`er	  treatment	  with	  GSK126	  or	  EPZ-­‐6438,	  and	  performing	  a	  
Western	  Blot	  with	  an$bodies	  for	  total	  H3,	  and	  mono-­‐,	  di-­‐,	  and	  tri-­‐methyla$on	  status.	  Successful	  
EZH2	  inhibi$on	  is	  indicated	  by	  increased	  demethyla$on	  on	  histone	  H3.	  Finally,	  GSK126	  and	  
EPZ-­‐6438	  were	  used	  in	  double-­‐agent	  dose	  response	  viability	  assays	  with	  other	  mul$ple	  myeloma	  
drugs,	  including	  the	  proteasome	  inhibitors	  Bortezomib	  and	  Oprozomib,	  and	  the	  histone	  
deacetylase	  inhibitor	  Panobinostat,	  to	  observe	  if	  these	  drugs	  worked	  synergis$cally.	  
B	  A	  
Figure	  2:	  EZH2	  expression	  levels	  and	  sensi.vity	  to	  GSK126.	  A)	  EZH2	  gene	  expression	  levels	  of	  HMCLs.	  EZH2	  expression	  was	  
determined	  by	  gene	  expression	  proﬁling	  (Aﬀymetrix)	  by	  Dr.	  Michael	  Kuehl	  (NCI)	  and	  Dr.	  Jonathan	  Keats	  (TGI,	  Phoenix).	  B)	  IC50s	  of	  
human	  mul$ple	  myeloma	  cell	  lines	  with	  GSK126.	  HMCLs	  presented	  from	  le`	  to	  right	  order	  from	  low	  to	  high	  EZH2	  expression.	  For	  
KMS20	  n=6,	  for	  KHM1B	  n=2,	  for	  NCIH929	  n=4,	  for	  MM1S	  P	  and	  VR	  n=4,	  for	  U266	  P	  and	  VR	  n=3,	  for	  XG2	  n=3,	  for	  MMM1	  n=5.	  Error	  bars	  
represent	  standard	  error	  of	  the	  mean.	  MOLP2,	  KAS61,	  OPM1	  all	  had	  n=1	  so	  SEM	  could	  not	  be	  calculated.	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Figure	  3:	  Methyla.on	  status	  of	  Histone	  H3	  aOer	  EZH2	  inhibi.on.	  Quan$ﬁca$on	  of	  the	  mono-­‐,	  di-­‐,	  and	  tri-­‐
methyl	  groups	  on	  Histone	  H3	  rela$ve	  to	  total	  H3	  levels	  a`er	  0-­‐5	  days	  of	  treatment	  with 5 µM GSK126	  or	  
EPZ-­‐6438.	  	  
Figure	  4:	  EZH2	  inhibitors	  in	  combina.on	  with	  other	  drugs.	  HMCL	  OCIMY1	  a`er	  48	  hours	  of	  treatment	  with	  0-­‐10	  
nM	  of	  the	  proteasome	  inhibitor	  Oz,	  0-­‐10	  nM	  of	  Oz	  with	  5	  μM	  GSK126,	  and	  0-­‐10	  nM	  of	  Oz	  with	  5	  μM	  EPZ-­‐6438.	  
Future Directions 
•  GSK126 reduces cell viability, with IC50s of 15-30 µM, 
independent of EZH2 expression level, while 
EPZ-6438 does not reduce cell viability on its own.  
•  Treatment with 5 µM GSK126 or EPZ-6438 effectively 
reduces the levels of di-methyl and tri-methyl groups 
on histone H3, but not levels of mono-methyl. This is 
most likely due to the low levels of mono-methyl 
groups that are present in the control. The 
demethylation effect is maximal after 4-5 days. 
•  Since GSK126 and EPZ-6438 both cause 
demethylation on histone H3, they are successfully 
inhibiting EZH2. However, this EZH2 inhibition occurs 
at a concentration (5 µM) that is much lower than the 
concentrations that induced apoptosis. This indicates 
that GSK126’s ability to induce apoptosis is due to an 
off-target effect. This effect is absent in EPZ-6438, 
which is why EPZ-6438 does not reduce viability. 
•  In some cell lines, non-cytotoxic doses of EZH2 
inhibitors work synergistically with proteasome 
inhibitors (Oz) and HDAC inhibitors (Panobinostat), 
causing more kill than Oz or Panobinostat on their 
own. 
 
•  Continue testing EZH2 inhibitors with proteasome 
inhibitors and HDAC inhibitors, including testing the 
effectiveness of pre-treating cells with EZH2 inhibitors 
and then treating with other classes of drugs. 
•  Determine which doses of GSK126 and EPZ-6438 
achieve maximal EZH2 inhibition. 
•  Explore mechanisms of synergy between EZH2 
inhibitors and proteasome/HDAC inhibitors. 
•  Determine if any HMCLs contain EZH2 mutations by 
cDNA sequencing with EZH2, since these cell lines may 
experience an apoptotic effect from EZH2 inhibition 
unlike wild type EZH2 HMCLs. They would also be much 
















































































Concentra.on	  of	  Oz	  (nM)	  
OCIMY1	  
Oz	  
Oz	  +	  GSK126[5uM]	  
Oz	  +	  EPZ-­‐6438[5uM]	  
Figure	  15:	  The	  func$ons	  of	  EZH2	  in	  cancer.	  EZH2	  silences	  tumor	  suppressor	  genes	  via	  the	  
methyla$on	  of	  histone	  H3	  on	  lysine	  27	  (H3K27).	  EZH2	  also	  methylates	  substrates	  other	  than	  
H3K27,	  and	  has	  a	  methyla$on-­‐independent	  mechanism	  of	  ac$on.	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